Kairos Pharma Ltd. (KAPA)
AMEX: KAPA
· Real-Time Price · USD
1.19
-0.06 (-4.80%)
At close: Oct 16, 2025, 3:59 PM
1.17
-1.68%
After-hours: Oct 16, 2025, 07:54 PM EDT
-4.80% (1D)
| Bid | 1.17 |
| Market Cap | 24.69M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -4.71M |
| EPS (ttm) | -0.27 |
| PE Ratio (ttm) | -4.41 |
| Forward PE | -3.54 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 1.18 |
| Volume | 329,519 |
| Avg. Volume (20D) | 1,213,687 |
| Open | 1.26 |
| Previous Close | 1.25 |
| Day's Range | 1.16 - 1.28 |
| 52-Week Range | 0.40 - 3.25 |
| Beta | 2.05 |
| Ex-Dividend Date | n/a |
About KAPA
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol KAPA
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for KAPA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts4 weeks ago
-20.24%
Kairos Pharma shares are trading lower. The compan...
Unlock content with
Pro Subscription
3 months ago
+70.8%
Kairos Pharma shares are trading higher after the company announced safety results from its Phase 2 trial of ENV-105 in advanced prostate cancer.
